# Effect of Dapagliflozin on Cardiac Structure, Function and Secondary Mitral Regurgitation in Patients with Left Ventricle Dysfunction

Study · id `cardio:ct-nct05849766` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05849766](<https://clinicaltrials.gov/study/NCT05849766>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT05849766

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 150 participants.

## Technical summary

Registry record NCT05849766. Randomized; no masking; primary purpose treatment. Start 2023-04-27 (actual); primary completion 2024-05-01 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 150 participants (enrolled count; ClinicalTrials.gov record NCT05849766, source copy `cardio:ctgov-nct05849766-2024-10-16`, retrieved 2026-10-31)
- Started: 2023-04-27 (actual) (ClinicalTrials.gov record NCT05849766, source copy `cardio:ctgov-nct05849766-2024-10-16`, retrieved 2026-10-31)
- Primary completion: 2024-05-01 (actual) (ClinicalTrials.gov record NCT05849766, source copy `cardio:ctgov-nct05849766-2024-10-16`, retrieved 2026-10-31)
- Completion: 2024-09-01 (actual) (ClinicalTrials.gov record NCT05849766, source copy `cardio:ctgov-nct05849766-2024-10-16`, retrieved 2026-10-31)
- Countries: Egypt (ClinicalTrials.gov record NCT05849766, source copy `cardio:ctgov-nct05849766-2024-10-16`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05849766-2024-10-16`, retrieved 2026-10-31)

## The registry's words

- Brief title: Effect of Dapagliflozin on Cardiac Structure, Function and Secondary Mitral Regurgitation in Patients with Left Ventricle Dysfunction
- Condition: Dilated Cardiomyopathy
- Intervention (Drug): Dapagliflozin Farxiga®
- Intervention (Drug): Ramipril Tritace®, Carvedilol Carvid®,and Spironolactone Aldactone®
- Lead sponsor: October 6 University
- Lead sponsor class: OTHER
- Collaborator: National Heart Institute, Egypt
- Collaborator class: OTHER\_GOV
- Collaborator: University of Florida
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Cardiomyopathy (heart muscle disease) (`cardio:cardiomyopathy`)
- Registry condition terms include this condition: Dilated cardiomyopathy (`cardio:dilated-cardiomyopathy`)
- Registry intervention name matches this record: Dapagliflozin (Farxiga) (`cardio:farxiga`)
- Registry lists this organization as a collaborator: National Heart Institute, Egypt (`cardio:org-national-heart-institute-egypt`)
- Registry lists this organization as a collaborator: University of Florida (`cardio:org-university-of-florida`)

## Provenance

Content hash: 09e183e1728061222600023ca60bd6fac38b0c41e032f441becd423fcfa7d231
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
